High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial

Journal of Clinical Oncology

Volumn 26, Issue 3, 2008, Pages 440-446

  Canioni, Danielle ^a   Salles, Gilles ^b   Mounier, Nicolas ^b   Brousse, Nicole ^b   Keuppens, Marie ^b   Morchhauser, Frank ^b   Lamy, Thierry ^b   Sonet, Anne ^b   Rousselet, Marie Christine ^b   Foussard, Charles ^b   Xerri, Luc ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STAINING; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; INTERFERON-ALPHA; LYMPHOMA, FOLLICULAR; MACROPHAGES; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TENIPOSIDE; TREATMENT OUTCOME;

EID: 38649108461     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.8298     Document Type: Article

References (23)

1. Hiddemann W, Buske C, Dreyling M, et al: Treatment strategies in follicular lymphomas: Current status and future perspectives. J Clin Oncol 23:6394-6399, 2005
2. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
3. Jaffe ES, Harris NL, Stein H, et al, eds: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001, pp 189-235
4. Koster A, van Krieken JH, Mackenzie MA, et al: Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 11:154-161, 2005
5. Zhao WL, Daneshpouy ME, Mounier N, et al: Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 103:695-697, 2004
6. Björck E, Ek S, Landgren O, et al: High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 105:2908-2915, 2005
7. Torlakovic EE, Bilalovic N, Golouh R, et al: Prognostic significance of PU.1 in follicular lymphoma. J Pathol 209:352-359, 2006
8. Michels J, Foria V, Mead B, et al: Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma. Br J Haematol 132:743-746, 2006
9. Glas AM, Kersten MJ, Delahaye LJ, et al: Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 105:301-307, 2005
10. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004
11. Carreras J, Lopez-Guillermo A, Fox BC, et al: High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108:2957-2964, 2006
12. Lee AM, Clear AJ, Calaminici M, et al: Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 24:5052-5059, 2006
13. Farinha P, Masoudi H, Skinnider BF, et al: Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106:2169-2174, 2005
14. Alvaro T, Lejeune M, Camacho FI, et al: The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 91:1605-1612, 2006
15. Alvaro T, Lejeune M, Salvado MT, et al: Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 24:5350-5357, 2006
16. Glas AM, Knoops L, Delahaye L, et al: Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25:390-398, 2007
17. Foussard C, Mounier N, Van Hoof A, et al: Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma (FL) patients. J Clin Oncol 24:424s, 2006 (suppl; abstr 7508)
18. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
19. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, et al: Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion. Immunobiology 211:487-501, 2006
20. Mantovani A, Sozzani S, Locati M, et al: Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549-555, 2002
21. Maloney DG, Smith B, Rose A: Rituximab: Mechanism of action and resistance. Semin Oncol 29:2-9, 2002 (1 suppl 2)
22. Cittera E, Leidi M, Buracchi C, et al: The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol 178:6616-6623, 2007
23. Lefebvre ML, Krause SW, Salcedo M, et al: Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: Mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 29:388-397, 2006